In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Controversies in the management of pulmonary hypertension and venous thromboembolism
Session

Event : ESC Congress 2019

Topic : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure - Treatment

  • Session type : Debate Session
  • Date : 01 September 2019
  • Time : 13:00 - 14:30

6 presentations in this session

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - PRO

Event : ESC Congress 2019

  • Session : Controversies in the management of pulmonary hypertension and venous thromboembolism
  • Speaker : L Mazzolai (Lausanne,CH)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - CON

Event : ESC Congress 2019

  • Session : Controversies in the management of pulmonary hypertension and venous thromboembolism
  • Speaker : N Meneveau (Besancon,FR)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - Discussion

Event : ESC Congress 2019

  • Session : Controversies in the management of pulmonary hypertension and venous thromboembolism

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - PRO

Event : ESC Congress 2019

  • Session : Controversies in the management of pulmonary hypertension and venous thromboembolism
  • Speaker : S Rosenkranz (Koln,DE)

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - CON

Event : ESC Congress 2019

  • Session : Controversies in the management of pulmonary hypertension and venous thromboembolism
  • Speaker : J Bermejo Thomas (Madrid,ES)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are